NVS Earnings

NVS reported its FY2025Q3 earnings on 2025-10-28, showcasing a revenue of 14.00B against an estimate of 14.00B, resulting in a 0.31% surprise. The EPS was 0, surpassing the expected 2.26 by 0% . The stock experienced a -4.42% price change on the earnings day and a -4.14% change over the next five days, reflecting market reactions to the results.

Following NVS's FY2025Q3 earnings announcement on 2025-10-28, the stock price moved by -4.42% on the day of the release. Over the subsequent five days, it saw a -4.14% change. Historically, NVS's stock price tends to shift by an average of +1.06% in the 10 days leading up to earnings and -0.44% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate NVS’s annual revenue to reach 14.00B, while the EPS is projected at 2.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.47% and EPS estimates Revise Upward by 0.77% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between NVS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 0.47%, while EPS estimates moved Revise Upward by 0.77% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, NVS's stock price typically moves by +1.06% in the 10 days before its earnings and -0.44% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 2.00 and revenue of 14.00B.

The earnings call summary indicates a positive outlook with strong sales growth, strategic product expansions, and a significant share buyback program. Despite some margin pressure from generic competition, Novartis plans to offset it with productivity improvements. The Q&A reveals confidence in product launches and market strategies, with no major negative sentiments from analysts. The upgraded guidance and share buyback plan further support a positive sentiment, suggesting a likely stock price increase of 2% to 8% over the next two weeks.